Dynavax Technologies
Emeryville, CA, United StatesIndustry
Dynavax makes the CpG 1018 vaccine adjuvant and has a plague vaccine candidate (rF1V-1018) that completed a Phase 2 trial under a US Department of Defense programme.
What it does
Threats covered
Categories
Profile
Dynavax Technologies is an Emeryville, California vaccine company that Sanofi acquired on 10 February 2026, making it an indirect wholly owned subsidiary. Its CpG 1018 adjuvant is used in the HEPLISAV-B hepatitis B vaccine and in plague vaccine development supported by the US Department of Defense.
More profile
The first rF1V-1018 phase 2 trial completed in April 2024, and a newer rF1V-1018 phase 2 trial began in September 2025 and is active but not recruiting, with primary completion expected in January 2027, according to ClinicalTrials.gov. Dynavax's main business is commercial vaccines rather than biodefence.
The founding year and the Sanofi deal value were not read.
Ownership
Wholly owned indirect subsidiary of Sanofi since 10 February 2026
Parent: Sanofi (checked)
Sources (5)
Not verified or not found
- Founding year: not read.
- Deal value: not read.
- DoD funding amounts: not read.
Questions
What does Dynavax Technologies do?
Dynavax makes the CpG 1018 vaccine adjuvant and has a plague vaccine candidate (rF1V-1018) that completed a Phase 2 trial under a US Department of Defense programme.
Where is Dynavax Technologies based?
HQ (as found): Emeryville, CA. HQ country: US.
Who owns Dynavax Technologies?
Wholly owned indirect subsidiary of Sanofi since 10 February 2026. Parent: Sanofi (checked)
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction